Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (21-30 of 676) with videos related to

Pageof 68
Sort By:
Leukemia Research|April 25, 2006
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targetingFrancis J Giles
The Australasian Nurses Journal|January 1, 1974
Unions--on maintaining social relevance in the era of the environmental revolutionR J Giles
Oncology (Williston Park, N.Y.)|July 10, 2002
The emerging role of angiogenesis inhibitors in hematologic malignanciesFrancis J Giles
The Oncologist|November 9, 2001
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignanciesF J Giles
Leukemia & Lymphoma|June 20, 2007
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AMLFrancis J Giles
Seminars in Hematology|July 23, 2009
New directions in the treatment of imatinib failure and/or resistanceFrancis J Giles
British Journal of Haematology|October 1, 1991
Maintenance therapy in the myeloproliferative disorders: the current optionsF J Giles
Leukemia Research|March 31, 2009
Laromustine: the return of alkylators to non-myeloablative therapy of AMLFrancis J Giles
Leukemia Research|April 27, 2010
Treating imatinib resistance in the few in CML-A key step towards cure in allFrancis J Giles
Equine Veterinary Journal|July 1, 1983
Outbreak of ragwort (Senecio jacobea) poisoning in horsesC J Giles
Pageof 68

Showing results (21-30 of 676) with videos related to

Sort By:
Pageof 68
Leukemia Research|April 25, 2006
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targetingFrancis J Giles
The Australasian Nurses Journal|January 1, 1974
Unions--on maintaining social relevance in the era of the environmental revolutionR J Giles
Oncology (Williston Park, N.Y.)|July 10, 2002
The emerging role of angiogenesis inhibitors in hematologic malignanciesFrancis J Giles
The Oncologist|November 9, 2001
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignanciesF J Giles
Leukemia & Lymphoma|June 20, 2007
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AMLFrancis J Giles
Seminars in Hematology|July 23, 2009
New directions in the treatment of imatinib failure and/or resistanceFrancis J Giles
British Journal of Haematology|October 1, 1991
Maintenance therapy in the myeloproliferative disorders: the current optionsF J Giles
Leukemia Research|March 31, 2009
Laromustine: the return of alkylators to non-myeloablative therapy of AMLFrancis J Giles
Leukemia Research|April 27, 2010
Treating imatinib resistance in the few in CML-A key step towards cure in allFrancis J Giles
Equine Veterinary Journal|July 1, 1983
Outbreak of ragwort (Senecio jacobea) poisoning in horsesC J Giles
Pageof 68